Next 10 |
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 38.2% to $0.24 on volume of 498,894,705 shares Qualigen Therapeutics Inc. (QLGN) rose 59.5% to $0.28 on volume of 243,116,946 shares NVIDIA Corporation (NVDA) fell 1.9% to $125.83 on volume o...
2024-06-24 00:00:05 ET Mike Matson from Needham issued a price target of $3.50 for PSNL on 2024-06-21 13:25:00. The adjusted price target was set to $3.50. At the time of the announcement, PSNL was trading at $1.22. The overall price target consensus is at $6.83 with hig...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD Cowen 3 rd Annual Tools / Dx Revolution Conference on Tuesday, June 25, 2024 at 5:30 p.m. Eastern Time. About Personalis, ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it has updated the ASCO data highlights conference call to Friday, June 21, 2024 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Personalis had previously announced it would host the conference ca...
Personalis will host a webinar call on June 19th, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time to present ASCO highlights from the conference Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium t...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal® , Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal resi...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT Personal ® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection w...
2024-05-09 10:00:35 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...
2024-05-08 23:53:08 ET Personalis, Inc. (PSNL) Q1 2024 Earnings Conference Call May 8, 2024 17:00 ET Company Participants Chris Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Rich Chen - Chief Medical Of...
2024-05-08 16:58:43 ET More on Personalis Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript Personalis Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Personalis Historical earnings data for Personalis Financial information for ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 38.2% to $0.24 on volume of 498,894,705 shares Qualigen Therapeutics Inc. (QLGN) rose 59.5% to $0.28 on volume of 243,116,946 shares NVIDIA Corporation (NVDA) fell 1.9% to $125.83 on volume o...
2024-06-24 00:00:05 ET Mike Matson from Needham issued a price target of $3.50 for PSNL on 2024-06-21 13:25:00. The adjusted price target was set to $3.50. At the time of the announcement, PSNL was trading at $1.22. The overall price target consensus is at $6.83 with hig...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD Cowen 3 rd Annual Tools / Dx Revolution Conference on Tuesday, June 25, 2024 at 5:30 p.m. Eastern Time. About Personalis, ...